Stock DESN DOTTIKON ES HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dottikon ES Holding AG

Equities

DESN

CH0582581713

Pharmaceuticals

Market Closed - Swiss Exchange
Other stock markets
 11:31:30 2024-04-26 am EDT 		5-day change 1st Jan Change
233 CHF +1.75% Intraday chart for Dottikon ES Holding AG +1.08% +1.75%
2023 Dottikon ES Posts Lower Fiscal H1 Net Income; Sales Up MT
2023 Dottikon ES Holding AG Reports Earnings Results for the Half Year Ended September 30, 2023 CI

Valuation

Fiscal Period: March 2019 2021 2022 2023 2024 2025 2026
Capitalization 1 556.3 2,522 3,500 3,583 3,211 - -
Enterprise Value (EV) 1 556.3 2,337 3,500 3,424 2,876 2,631 2,688
P/E ratio 34.2 x - 59.2 x 40.9 x 32.5 x 31.3 x 31.7 x
Yield - - - - - - -
Capitalization / Revenue - 11.5 x 13.9 x 11.2 x 8.99 x 8.12 x 7.19 x
EV / Revenue - 10.7 x 13.9 x 10.7 x 8.05 x 6.66 x 6.02 x
EV / EBITDA - 29.3 x 39.4 x 29.4 x 20.8 x 17.9 x 16.5 x
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - 3.52 x - 4.47 x 3.61 x 2.89 x 2.68 x
Nbr of stocks (in thousands) 12,502 13,780 13,780 13,780 13,780 - -
Reference price 2 44.50 183.0 254.0 260.0 233.0 233.0 233.0
Announcement Date 5/28/19 5/28/21 5/31/22 5/31/23 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2021 2022 2023 2024 2025 2026
Net sales 1 - 218.9 251.9 319.5 357.3 395.3 446.9
EBITDA 1 - 79.78 88.79 116.6 138.1 147.3 163.3
EBIT 1 - 60.64 67.66 96 117 122.5 122.2
Operating Margin - 27.7% 26.86% 30.05% 32.75% 30.99% 27.34%
Earnings before Tax (EBT) - - - - - - -
Net income 16.26 - 59.3 - - - -
Net margin - - 23.54% - - - -
EPS 2 1.300 - 4.290 6.350 7.160 7.449 7.352
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 5/28/19 5/28/21 5/31/22 5/31/23 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: März 2022 S1 2023 S1 2024 S1
Net sales 1 - 133.8 152.6
EBITDA 1 - 47.1 52.62
EBIT 1 - 37.5 42.57
Operating Margin - 28.03% 27.91%
Earnings before Tax (EBT) - - -
Net income 1 23.92 38.9 37.38
Net margin - 29.07% 24.5%
EPS - - -
Dividend per Share - - -
Announcement Date 11/26/21 11/29/22 11/28/23
1CHF in Million
Estimates

Balance Sheet Analysis

Fiscal Period: März 2019 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 185 - 159 335 579 523
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - 9.89% - 11.6% 11.7% 10.1% 8.6%
ROA (Net income/ Total Assets) - - - - - - -
Assets - - - - - - -
Book Value Per Share 2 - 52.00 - 58.10 64.50 80.70 86.80
Cash Flow per Share 2 - 4.760 2.620 6.480 8.150 8.120 8.800
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 5/28/19 5/28/21 5/31/22 5/31/23 - - -
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dottikon ES Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
233
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
DOTTIKON ES HOLDING AG Stock Dottikon ES Holding AG
+1.75% 3.51B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DESN Stock
  4. Financials Dottikon ES Holding AG